Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 Jan 17

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 Jan 17

DOI: 10.23736/S1824-4785.18.02985-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer

Daniele A. PIZZUTO 1 , Salvatore ANNUNZIATA 1, Francesco P. IERIA 1, Carmelo CALDARELLA 2, Maria A. ISGRÒ 3, Valerio LANNI 2, Gaia BENCIVENGA 4,Vittoria RUFINI 1, Alessandro GIORDANO 1

1 Institute of Nuclear Medicine, "Università Cattolica del Sacro Cuore "A. Gemelli", Rome, Italy; 2 Nuclear Medicine Unit, Policlinico "A. Gemelli", Rome, Italy; 3 Laboratorio Analisi Chimico-Cliniche ed Ematologiche, Ospedale di Circolo e Fondazione Macchi, Varese, Italy; 4 PET-CT Center, Policlinico “A. Gemelli”, Rome, Italy


PDF  


BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs.
METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014. Patients with lung lesion with F-18-FECh uptake were included. Data concerning GS at diagnosis, “trigger” prostate-specific antigen (PSAtr), PSA doubling time (PSAdt), PSA velocity (PSAvel) and ongoing androgen deprivation therapy were collected. PET-CT findings were confirmed by histology or followup (FU) and classified as follows: inflammation, primary lung cancer or metastases from tumour other than PC, and lung metastases from PC.
RESULTS: Twenty-two patients with F-18-FECh positive lung lesion and available histology or FU were identified. PSAdt was significantly (p=0.029) shorter in patients with lung metastases from PC (median PSAdt 1.7 months, interquartile range [IQR] 1.5-4.1 months) than in patients without lung PC relapse (median PSAdt 6.7 months, IQR 3.9-7.8); PSAvel was significantly (p=0.019) higher in patients with lung metastases from PC (median PSAvel 3.2 ng/ml/month, IQR 0.65-6.65 ng/ml/month) than in patients without lung PCrelapse (median PSAvel 0.3 ng/ml/month, IQR 0.2-0.5 ng/ml/month). Patients with lung metastases from PC had significantly (p=0.006) higher GS at diagnosis (median GS 8) than the other ones (median GS 7).
CONCLUSIONS: Our analysis shows that the prevalence of F-18-FECh positive lung metastases in patients with PC, especially with higher GS at diagnosis, is higher in presence of a steady increase in PSA values, confirmed by higher PSAvel and shorter PSAdt.


KEY WORDS: Prostate - Lung - Metastases - Choline - Biochemical relapse

top of page

Publication History

Article first published online: January 17, 2018
Manuscript accepted: January 11, 2018
Manuscript revised: November 15, 2017
Manuscript received: February 19, 2017

Cite this article as

Pizzuto DA, Annunziata S, Ieria FP, Caldarella C, Isgrò MA, Lanni V, et al. Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer. Q J Nucl Med Mol Imaging 2018 Jan 17. DOI: 10.23736/S1824-4785.18.02985-0

Corresponding author e-mail

dapizzuto@gmail.com